Deep brain stimulation of the subthalamic nucleus in Parkinson disease 2013–2023: where are we a further 10 years on?

Abstract

Deep brain stimulation has been in clinical use for 30 years and during that time it has changed markedly from a small-scale treatment employed by only a few highly specialized centers into a widespread keystone approach to the management of disorders such as Parkinson’s disease. In the intervening decades, many of the broad principles of deep brain stimulation have remained unchanged, that of electrode insertion into stereotactically targeted brain nuclei, however the underlying technology and understanding around the approach have progressed markedly. Some of the most significant advances have taken place over the last decade with the advent of artificial intelligence, directional electrodes, stimulation/recording implantable pulse generators and the potential for remote programming among many other innovations. New therapeutic targets are being assessed for their potential benefits and a surge in the number of deep brain stimulation implantations has given birth to a flourishing scientific literature surrounding the pathophysiology of brain disorders such as Parkinson’s disease. Here we outline the developments of the last decade and look to the future of deep brain stimulation to attempt to discern some of the most promising lines of inquiry in this fast-paced and rapidly evolving field.

Keywords:

• Deep brain stimulation
• Parkinson’s disease
• subthalamic nucleus
• neurodegenerative disease
• medical technology
• brain-machine interfacing
• artificial intelligence

Disclosure statement

The authors declare that they have received no commercial or charitable funding contributing to the production of the following article. KA has received educational grants from Medtronic and Abbott Companies.

References